Related Experiment Video
Updated: May 19, 2026

08:26
Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
Resect and discard strategy in clinical practice: a prospective cohort study
S Paggi1, E Rondonotti, A Amato
1Division of Gastroenterology, Valduce Hospital, Como, Italy.
Endoscopy
|August 4, 2012
Summary
The "resect and discard" strategy using narrow-band imaging (NBI) for small colonic polyps is safe and effective. This approach allows surveillance intervals to be determined without histopathology, improving cost-effectiveness.
Area of Science:
- Gastroenterology
- Endoscopy
- Oncology
Background:
- Narrow-band imaging (NBI) shows promise in differentiating adenomatous from non-adenomatous colonic polyps.
- A "resect and discard" strategy using NBI could enable surveillance intervals to be set without histopathology for small polyps (<10 mm).
Purpose of the Study:
- To evaluate the feasibility and safety of the NBI-assisted "resect and discard" strategy in routine clinical practice for small colonic polyps.
Main Methods:
- Prospective inclusion of consecutive colonoscopy outpatients with small polyps (<10 mm).
- Endoscopic categorization of polyps as adenoma or non-adenoma using simplified NBI criteria.
- Assignment of post-polypectomy surveillance intervals based on NBI findings, with subsequent comparison to histology-based intervals.
Main Results:
- NBI demonstrated high sensitivity (94.9%) and accuracy (85.7%) for in vivo adenoma diagnosis.
- The NBI-directed surveillance strategy aligned with the histology-directed strategy in 82.9% of patients.
- The strategy could lead to early or delayed surveillance in 9.8% and 7.3% of patients, respectively.
Conclusions:
- The "resect and discard" strategy is a viable, safe, and cost-effective approach for managing patients with small colonic polyps.
- Caution is advised for polyps 6-9 mm and right-sided lesions due to their malignant potential.
- The study was registered on Clinicaltrials.gov (NCT01462123).

